| 000 | 01770 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516223254.0 | ||
| 264 | 0 | _c20170914 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1535-1386 | ||
| 024 | 7 |
_a10.2106/JBJS.M.00862 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEl-Hoss, J | |
| 245 | 0 | 0 |
_aA Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis. _h[electronic resource] |
| 260 |
_bThe Journal of bone and joint surgery. American volume _cJul 2014 |
||
| 300 |
_ae117 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenzamides _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Morphogenetic Protein 2 _xadministration & dosage |
| 650 | 0 | 4 |
_aDiphenylamine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNeurofibromatosis 1 _xcomplications |
| 650 | 0 | 4 |
_aOsteogenesis _xdrug effects |
| 650 | 0 | 4 |
_aPseudarthrosis _xdrug therapy |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 |
_aTransforming Growth Factor beta _xadministration & dosage |
| 700 | 1 | _aCheng, T | |
| 700 | 1 | _aCarpenter, E C | |
| 700 | 1 | _aSullivan, K | |
| 700 | 1 | _aDeo, N | |
| 700 | 1 | _aMikulec, K | |
| 700 | 1 | _aLittle, D G | |
| 700 | 1 | _aSchindeler, A | |
| 773 | 0 |
_tThe Journal of bone and joint surgery. American volume _gvol. 96 _gno. 14 _gp. e117 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2106/JBJS.M.00862 _zAvailable from publisher's website |
| 999 |
_c24013746 _d24013746 |
||